Zafgen Inc. (NASDAQ:ZFGN)’s share price fell 2.2% during trading on Tuesday . The company traded as low as $3.05 and last traded at $3.05, with a volume of 623,407 shares trading hands. The stock had previously closed at $3.12.

A number of research firms have commented on ZFGN. FBR & Co restated a “buy” rating on shares of Zafgen in a research report on Monday, June 13th. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Thursday, May 12th. Leerink Swann reaffirmed a “market perform” rating and issued a $6.00 target price on shares of Zafgen in a research note on Wednesday, July 20th. Cowen and Company downgraded shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 20th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $19.00 target price on shares of Zafgen in a research note on Tuesday, April 5th. Six research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Zafgen has a consensus rating of “Hold” and a consensus target price of $9.22.

The firm’s market capitalization is $84.27 million. The firm has a 50 day moving average price of $5.96 and a 200-day moving average price of $6.49.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.09. During the same period in the prior year, the company posted ($0.53) earnings per share. On average, analysts predict that Zafgen Inc. will post ($2.62) EPS for the current year.

In other news, CFO Patricia L. Allen acquired 16,000 shares of the firm’s stock in a transaction on Tuesday, July 26th. The stock was acquired at an average price of $3.12 per share, for a total transaction of $49,920.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frances K. Heller acquired 10,000 shares of the firm’s stock in a transaction on Friday, July 22nd. The stock was purchased at an average price of $2.99 per share, with a total value of $29,900.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $29,900. The disclosure for this purchase can be found here.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.